Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry

Dyne Therapeutics (NASDAQ:DYN) is one of the 17 biotechnology stocks with more than 50% upside. As of the February 12 closing, Dyne Therapeutics (NASDAQ:DYN) held a strongly bullish consensus view. Of the 9 analysts covering the stock, 7 assigned Buy ratings and 2 issued Hold ratings. With no Sell rating, the stock has a projected median 1-year price target of $39.33, implying almost 146% upside. Billion Photos/Shutterstock.com On January 20, Dyne Therapeutics (DYN) reported that Japan’s Ministry of He ...